Back to today’s briefing

Story perspectives

Weight Loss Drug Program Paused Amid Rising Costs

1/3/2025

50 6

Summary

Story summary

Lory Osborn's inspiring 75-pound weight loss journey with Wegovy faces a setback as West Virginia pauses its weight loss drug program due to rising costs. This decision echoes a national trend, with insurers pulling back on coverage. Experts praise GLP-1 drugs for curbing cravings, while pharmaceutical giants see a lucrative future in obesity treatments.

1 of 1

Story summary

Lory Osborn's inspiring 75-pound weight loss journey with Wegovy faces a setback as West Virginia pauses its weight loss drug program due to rising costs. This decision echoes a national trend, with insurers pulling back on coverage. Experts praise GLP-1 drugs for curbing cravings, while pharmaceutical giants see a lucrative future in obesity treatments.